Citation index
Juris J. Meier, MD
Ruhr University Bochum, St. Josef-Hospital
Diabetologist whose published work covers beta-cell biology, the incretin effect, and the comparative pharmacology of incretin-based therapies.
Public profiles
Cited on Peptides Research Hub
- Tirzepatide: research, pharmacology, and clinical evidence
Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist approved for T2DM (Mounjaro) and chronic weight management (Zepbound). This pillar covers mechanism, half-life, bioavailability, pivotal trials, safety, and regulatory status.
- Tirzepatide mechanism of action: dual GIP and GLP-1 receptor agonism
Tirzepatide
Tirzepatide activates both the GIP and GLP-1 receptors via a single 39-residue peptide with biased GLP-1 signaling and full GIP agonism. This article reviews structural design, receptor coupling, and downstream metabolic effects.
- Tirzepatide Half-Life and Pharmacokinetics
Tirzepatide
Tirzepatide's mean terminal half-life is approximately 116.7 hours (≈ 5 days). This article covers absorption, distribution, the C20 fatty diacid albumin-binding strategy, and Aib2/Aib13 protection against DPP-4 cleavage.
- Tirzepatide Safety Profile and Adverse Events in the Literature
Tirzepatide
This article summarizes adverse events from the SURPASS and SURMOUNT trial programs, the FDA boxed warning for thyroid C-cell tumors, and known cautions in pancreatitis, gallbladder disease, gastroparesis, and pregnancy.